Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Methotrexate and hydroxychloroquine split on cardiovascular outcomes in RA

Key clinical point: A composite major cardiovascular event outcome did not differ significantly between treatment groups.

Major finding: MI incidence was higher in people taking hydroxychloroquine versus methotrexate.

Study details: Observational study of 35,699 people taking methotrexate and 23,630 taking hydroxychloroquine.

Disclosures: The division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women’s Hospital supported the study. Dr. Kim has received support for Brigham and Women’s Hospital for unrelated research from Pfizer, AbbVie, Roche, and Bristol-Myers Squibb. Several other coauthors reported having financial relationships with pharmaceutical companies that make drugs for RA.


He M et al. Arthritis Rheumatol. 2020;72(suppl 10): Abstract 1993.